Vision loss from genetic defects may no longer represent a permanent sentence. This breakthrough addresses X-linked retinoschisis, a hereditary condition affecting roughly 1 in 15,000 males worldwide, where defective RS1 gene expression leads to retinal splitting and progressive blindness often beginning in childhood. The subretinal gene therapy approach delivers functional RS1 genes directly to photoreceptor cells using viral vectors, targeting the root molecular cause rather than managing symptoms. Clinical trial participants demonstrated measurable improvements in visual acuity and retinal structure over the monitoring period, with some patients gaining multiple lines of vision on standard eye charts. The therapy appears to stabilize the characteristic retinal splitting pattern that defines this condition. This represents a significant advancement in treating inherited blindness, joining a growing arsenal of gene therapies for retinal diseases including Luxturna for Leber congenital amaurosis and recent trials for Stargardt disease. The subretinal injection technique requires surgical precision but has established safety profiles from previous retinal gene therapy trials. However, several factors temper immediate enthusiasm. The durability of visual improvements remains unknown, as does the optimal timing for intervention - whether early treatment prevents degeneration better than later intervention. The therapy targets only one specific genetic variant among hundreds that cause inherited blindness. Cost and accessibility will likely limit initial availability to specialized medical centers. While this study confirms the viability of gene correction for retinal diseases, the field still faces challenges in scaling personalized genetic treatments across the diverse spectrum of inherited eye conditions affecting millions globally.